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Role of Methyltransferase Like-3 (METTL3) in Pancreatic Ductal Adenocarcinoma (PDAC) 
Progression 
Bhargavi Brahmendra Barathi, B. Tech; Advisor: Dr. Anirban Maitra, MBBS 
 
Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive cancer with about a 10% five-year 
survival rate. The grim prognostic situation of pancreatic cancer patients underlines the need to 
identify novel molecular targets. Recent studies have brought to attention, the need to 
therapeutically exploit epigenetic pathways, apart from only targeting genetic mutations to 
effectively combat PDAC. To that effect, METTL3-mediated post-transcriptional methylation of RNA 
transcripts have been shown to contribute to cancer progression in multiple cancer types. 
METTL3 deposits methyl groups onto adenosine bases within specific consensus sequences in RNA, 
resulting in the formation of N-6 methyl adenosine (m6A). m6A is the most abundant internal 
modification in mRNA and affects gene expression while also playing crucial roles in early-stage 
development, organogenesis, and cell-fate determination. 
To investigate the effect of METTL3 in PDAC, we analyzed TCGA RNA-Seq expression profile data for 
the PAAD patient cohort and found that METTL3 expression is positively correlated with patient 
survival. The difference in median survival between patients expressing METTL3 at a higher level 
than average compared to patients expressing low levels of METTL3 was 6 months. We generated 
METTL3 knockdown clones of human pancreatic cancer cell lines (Panc-1 and MiaPaca-2) using 
shRNA targeting and performed in vitro assays to determine differences in growth and migratory 
characteristics upon METTL3 knockdown. METTL3 loss decreased proliferation and migration rates 
in MiaPaca-2 cells and decreased proliferation rate in Panc-1 cells when compared to control cell 
lines. As METTL3 is physiologically important in inducing differentiation and repressing pluripotent 
identity, we investigated the effect METTL3 knockdown exerts on EMT-associated markers in these 
pancreatic cancer cell lines. We found that in the epithelial cell line, Panc-1 upon METTL3 
knockdown there was a reduction in E-Cadherin expression, along with a concordant increase in N-
Cadherin and Vimentin expression. Our results indicate that expression of METTL3 positively 
regulates patient survival in PDAC, reduces proliferation and migration rates of pancreatic cancer 
cell lines, and induces an EMT-like phenotype. 
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1.1 Pancreatic Ductal Adenocarcinoma:  
 
Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive cancer of the exocrine section of the 
pancreas with a grave 5-year survival rate of about 10%.(1) Even though the Surveillance, 
Epidemiology, and End results (SEER) program of the National Cancer Institute only estimated PDAC 
to be the eleventh most common cancer in the US in 2020, which accounted for 3.2% of total new 
cancer cases, it was the third most leading cause of cancer-related deaths, that year. PDAC is also set 
to become the second leading cause of cancer-related deaths, only behind lung cancers by 2030.(2) 
Effective combative strategies to fight PDAC have been hindered due to a variety of factors. Lack of 
symptoms in the early stages of the disease leads to it being detected at a later stage, contributing to 
the bleak survival rate.(3) Progression of the disease occurs in distinct histopathological stages 
involving the sequential activation or suppression of different oncogenes and tumor suppressors, 
respectively. The most common pathological stage considered to be a precursor to adenocarcinoma 
of the pancreas is the Pancreatic Intraepithelial neoplasia (PanIN) stage. PanINs are lesions occurring 
in small pancreatic ducts that can only be observed under the microscope. Pathologists had originally 
adopted three degrees of grading the PanINs (grade 1-3), but are now moving to a two-tiered system 
being, low grade and high grade PanIN.(4),(5)  Treating PDAC as a standard involves resecting the 
tumor surgically, along with administering adjuvant chemotherapy.(5) One of the key impeding 
factors to successful treatment has also been the development of therapeutic resistance to 
chemotherapy.(6) Disease recurrence can occur by way of undetected micrometastasis, also leading 
to a roadblock in treatment.(7)  
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1.2 Causes and risk factors of Pancreatic Cancer: 
1.2.1 Age 
 
Though one singular cause of pancreatic cancer is unknown, there are a plethora of risk 
factors that contribute to the development of the disease. Age is a known non-modifiable risk factor 
in the pancreatic cancer narrative. The proportion of risk involved in developing pancreatic cancer is 
in direct correlation with aging. Patients presenting with pancreatic cancer are usually older 
individuals. Diagnosing the cancer in patients under thirty years of age is uncommon.(5),(8). 65 to 74 
years of age is reported to be the most frequent window when pancreatic cancer is diagnosed in in 
the United States, with a median age of 70.(1) The highest mortality rates are also reported within the 
same 65-74 years window, with the median age at death being 72.(1)  
1.2.2 Sex 
Some of the demographic factors that contribute to an increased risk of pancreatic cancer are 
sex and ethnicity. Men are, on average more likely to develop pancreatic cancer compared to 
women.(1) According to the Global Cancer Observatory, in 2020, males across the globe had an age-
standardized rate (ASR) of incidence of pancreatic cancer of 5.7, compared to women that had an ASR 
of 4.1.(9) Although some studies suggest that this variation may be brought about by environmental 
risk factors such as a higher prevalence of smoking among men, it is unlikely to be the sole cause. 
Other host genetic factors that could potentially be contributing to this higher incidence in men are 
yet to be uncovered.(10) 
1.2.3 Ethnicity  
Historically, racial differences have been attributed to display significant variation in 
pancreatic cancer incidence and mortality rates. In the United States, patients of African American 
origin report higher numbers when compared to Caucasians and Asian Americans.(8) Ashkenazi Jews 
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are also known to possess a higher susceptibility to developing pancreatic cancer as a result of their 
genetic make-up.(11),(12) 
1.2.4 Smoking 
Several studies have been conducted to determine the effects various environmental risk 
factors exert on pancreatic cancer incidence. A conclusive detrimental relationship between smoking 
and about two-fold increase in risk of developing pancreatic cancer has been established.(13),(14) 
Independent studies on both animals and epidemiological data have confirmed that cigarette smoking 
and tobacco are carcinogens, in the pancreatic context.(11) Some groups have reported a dose-
dependent effect to the number of cigarettes smoked and length of exposure, while some have 
claimed an inconclusive correlation.(13) A 2012 study revealed that nicotine, one of the major 
constituents of a cigarette, activates Src kinase promoting pancreatic cancer progression and 
metastasis.(15) Alcohol consumption, on the other hand has not revealed a convincing correlation to 
be a risk factor for pancreatic cancer incidence.(13)  
1.2.5 Alcohol 
The results from various studies determining the degree of risk alcohol poses to pancreatic 
cancer incidence have been mixed and the field seems to be split on the verdict. However, alcoholism 
or chronic overindulgence of alcohol is a major contributor to chronic pancreatitis, which is a well-
documented risk factor for PDAC incidence.(16) This warrants us to treat alcohol as a potential risk 
factor for pancreatic cancer incidence and advocate for decreased alcohol consumption, as part of a 
holistic lifestyle change. 
1.2.6 Obesity 
Obesity is an important pancreatic cancer risk factor that has a bearing on millions of people 
across the globe, ever more so in a developed nation, such as the United States. Individuals with a 
Body Mass Index (BMI) of greater than or equal to 30, are considered obese and possess a less than 
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fivefold increase in risk of PDAC incidence.(12) A World Cancer Research Fund pancreatic cancer 
report in 2012, referenced several studies that demonstrated a higher risk of pancreatic cancer in 
obese individuals and showed that for increases in every 5 BMI units, the risk increased by 10%, 
regardless of gender of the patient.(5) Obesity has also been associated with the onset of Type 2 
diabetes, which is a known risk factor for pancreatic cancer. 
1.2.7 Chronic Pancreatitis 
Chronic pancreatitis (CP), as the name suggests, is an inflammation of the pancreas that 
progresses over time. It is accompanied by acinar cell destruction, fibrosis, and an eventual inability 
of the patient to digest food and secrete pancreatic hormones.(8),(17) CP is considered a risk factor 
that predates pancreatic cancer in patients. Although it is a risk factor, there is considerable overlap 
between most symptoms of the two conditions, making the diagnosis of pancreatic cancer 
difficult.(13) Chronic pancreatitis can be caused by hereditary (somatic mutations), environmental 
(alcohol or cigarette smoking), or idiopathic factors. It has been reported that when comparing alcohol 
related chronic pancreatitis with genetic idiopathic chronic pancreatitis, the latter poses a higher risk 
of pancreatic cancer.(18) Of all the chronic pancreatitis patients, when we monitor them over a 20-
year period, about 5% of them develop pancreatic cancer.(5),(19) 
1.2.8 Genetic Factors 
Pancreatic cancer, at the root of the disease is genetic and can be caused by inherited and 
acquired mutations. Family history also plays a significant role as a risk factor contributing to 
pancreatic cancer incidence, wherein it can be classified as familial incidence of the cancer. Familial 
pancreatic cancer is defined as when two or more first-degree relatives of a patient currently have or 
previously have been diagnosed with pancreatic cancer, in the absence of other known genetic 
conditions.(5),(12) There is an exponential increase in risk with the number of first-degree relatives 
involved that have pancreatic cancer. Specific familial genetic syndromes also contribute to an 
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increased risk of developing pancreatic cancer, through germline mutations in certain genes. Some of 
them include hereditary breast cancer (mutations in BRCA1, BRCA2), hereditary pancreatitis (PRSS1 
gene is affected), familial atypical multiple-mole melanoma (p16/CDKN2A is mutated), and Peutz-
Jeghers syndrome (STK11/LKB1 mutations).(5),(8),13,(20),(21) 
A majority of the pancreatic cancer cases arise due to mutations that occur randomly, as 
opposed to inherited familial cancer.(8) Though many hundreds of genes are mutated in a pancreatic 
cancer tumor, variable across patients, a select list of genes have been identified to be common across 
the patient population, believed to be driving this malignancy. They include mutations in well-known 
cancer associated genes and other relevant signaling pathways. Collectively known as the genetic 
drivers of PDAC, their expression patterns have been shown to denote the sequential 
histopathological stages of the disease.(22) 
1.3 Common genetic drivers of PDAC: 
 
Mutations in the K-RAS oncogene were the first to be discovered as playing a role in 
pancreatic cancer initiation.(23) Point mutations arising in codon 12 of the oncogene, activate it to 
express a mutated form of the Ras protein. These mutations, substituting the glycine with now, valine, 
aspartate, or arginine are detectable in about 30% of early neoplastic lesions and are almost 
ubiquitous in advanced tumors.(22),(24) K-RAS mutations have been shown to be the earliest genetic 
perturbation in the progression of PanINs in humans.(22) Activating oncogenic mutations in K-RAS 
bring about downstream cellular effects promoting tumor growth by engaging different signaling 
pathways including RAF-MAPK and PI3K.(22),(25),(26) 
Loss of the CDKN2A gene and mutations in the tumor-suppressor P53 are also both commonly 
observed in the later stage of PDAC progression.(25)  Mutations in the P53 gene occur as missense 
alterations in later stage PanINs. CDKN2A gene encodes two tumor suppressor genes at the 9q21 
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locus, INK4A and ARF. With the loss of CDKN2A, both INK4A and ARF are lost in most pancreatic 
tumors.(23)  
SMAD4 is also a frequently altered gene in pancreatic cancers, which is an important regulator of 
the TGF-B signaling pathway. This mutation is observed in approximately half of the pancreatic 
cancer population.(23) 
 
Figure 1: Histopathological progression of pancreatic cancer with temporal expression of genetic 
drivers.  (Bardeesy, N. & DePinho, R. A. Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2, 






1.4 METTL3 and N-6 methyl adenosine (m6A): 
 
Methyltransferase-like 3 (METTL3) is a 70kDa protein that is encoded by the METTL3 gene and 
methylates RNAs, including but not limited to mRNA, tRNA, lncRNA.(27) METTL3 along with METTL14 
and WTAP proteins forms the methyltransferase writer complex or the m6A-METTL complex (MAC 
complex).(28) METTL3 acts as the methylator in the complex, and hence referred to as the writer. 
METTL14 provides structural support to METTL3 but does not methylate RNA transcripts.(29) METTL3 
catalyzes the addition of a methyl group onto specific adenosine residues in the RNA, forming N-6 
methyladenosine. This methylation is not a stochastic process but occurs within identified consensus 
motifs in the RNA.  In the mRNA, the methylation is also preferentially enriched close to the stop 
codon, 3’ UTR and long internal exons.(30) There are other key protein players in the methylation 
cascade known as readers and erasers. Erasers reverse the methylation, reverting the molecule to an 
adenosine once again. Readers, like the YTHDF and IGF2BP family of proteins recognize and bind to 
the methyl mark to bring about downstream effects on gene expression. ALKBH5 and FTO are two key 
demethylases considered erasers of this modification.(31),(32) 
 











1.5 Physiological effects and functions of METTL3 mediated m6A RNA methylation 
 
m6A RNA methylation leads to a variety of effects on gene expression. Reader proteins are 
recruited to the methylation site that can then recognize and bind to effect these downstream 
changes. mRNA structure, mRNA splicing, mRNA half-life, mRNA export, and mRNA translational 
efficiency are influenced by the deposition of m6A marks.(32) YTHDF1 increases translational 
efficiency of methylated RNA transcripts while YTHDF2 reduces half-life of methylated transcripts. 
These are two key downstream effects of the m6A RNA methylation that have the most significant 
bearing on the human transcriptome.  
From previously published studies understanding normal physiology, we know that METTL3 
plays a key role in regulating early embryogenesis,(33)  circadian rhythm of metabolic processes,(34) 
innate immunity,(35) and long-term memory(36) among a whole host of other functions. An 
important contribution of METTL3 and its associated methylation is the role it plays in early 
development and cellular differentiation. Geula et al. showed that METTL3 is important in regulating 
the transition of naïve pluripotent cells to differentiating towards a specific lineage. They cultured 
mouse embryonic stem cells (mESC) from a mouse with a METTL3 knockout (KO) and outlined that 
when conditioned to develop into a specific lineage, the cells still showed sustained expression of 









Figure 3: Embryonic stem cells with METTL3 knockout maintain pluripotent identity and fail to 
differentiate into a specific lineage. 
(Geula, S. et al. m6A RNA methylation facilitates resolution of naive pluripotency toward 
differentiation. Science (80-. ). 347, 1002–1006 (2015). Used with permission form Copyright 





1.6 METTL3 and m6A methylation in cancer: 
 
METTL3 expression and METTL3-mediated m6A RNA methylation have been recently 
uncovered to be playing critical roles in a variety of different cancers. METTL3, according to previous 
work by other groups can affect malignancies by playing tumorigenic or tumor suppressive roles, both 
directly by expression of the protein and/or deposition of the methyl mark on specific RNA transcripts. 
In most of the cancers where researchers have elucidated the mechanism as to how METTL3 
affects the pathogenesis of that cancer, we can note that METTL3 methylates specific RNAs, modifying 
them post-transcriptionally to now contribute to the carcinoma. For example, in lung 
adenocarcinoma, METTL3 mediated m6A methylation on YAP, TAZ genes increase their translational 
efficiency, leading to an elevated expression. This elevation in expression increases cell proliferation 
and invasion. The normal physiological downstream effect of increase in translation when m6A 
methylation occurs is exploited by cancer cells to further their cause.(38) Similarly, in acute myeloid 
leukemia, there occurs a preferential increase in methylation in genes regulating apoptosis and 
differentiation, like MYC, BCL2, and PTEN.(39) As these examples showcase, in both these cases 
METTL3 plays a tumor promoting role and aids in the progression of the cancer. 
On the contrary, the overall survival of renal cell carcinoma (RCC) patients showed a positive 
correlation to METTL3 expression levels. Additionally, there was an increase in proliferation and 
migration in RCC cell lines when METTL3 was knocked down. Xiao et al noted that METTL3 acts as a 
tumor suppressor in renal cell carcinoma by potentially affecting the PI3K/Akt/mTOR pathway.(40) In 
PDAC, however METTL3 and/or METTL3 mediated m6A methylation affects the progression of the 




1.7 METTL3 and Epithelial to Mesenchymal Transition in cancer: 
 
One of the noteworthy ways in which METTL3 affects cancer progression is by methylating 
specific transcripts involved in key pathways, contributing to cellular proliferation and survival of the 
tumor. In Hela cells, the increased abundance of m6A marks on Snail mRNA induces translation and 
drives the cells towards epithelial to mesenchymal transition (EMT).(41) EMT is a phenomenon of 
cancer cells wherein which they lose epithelial characteristics while acquiring mesenchymal 
characteristics, allowing them to migrate and form secondary tumors or metastasis.(42) This is 
induced by the repression of specific proteins conferring an epithelial state (E-Cadherin, Occludin, 
Claudin, Cytokeratin) and the activation of proteins associated with the mesenchymal state (N-
Cadherin, Vimentin, Fibronectin).(42) While cancer cells undergo EMT, they also acquire stem-cell like 
features. METTL3 expression as detailed above, is important in the repression of pluripotent identity. 
These factors present the need to explore the role METTL3 and m6A methylation play in the induction 














Figure 4: Epithelial to Mesenchymal Transition in Cancer 
(Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal 
transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69-84. 
doi:10.1038/s41580-018-0080-4. Used with permission from Copyright Clearance Center. 




















2. Hypothesis and aims: 
 
The proportion of pancreatic cancer incidence rates to the mortality rates every year in the US is 
almost close to 1, showcasing the aggressive nature of the cancer. The disease is invariably fatal with 
only 9.3% of patients having survived beyond the 5-year mark between 2009 and 2015 according to 
the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute. 
Treatment options, though have continuously evolved, over the last few decades, there has only been 
a marginal increase in survival rates. Given the heterogeneity in treatment outcomes among 
pancreatic cancer patients, there is a timely clinical need to investigate novel genes and molecular 
signaling pathways.  
In understanding the influence of epigenetic modifications on cancer initiation and progression, 
various groups have implicated RNA methyltransferase, METTL3 in a slew of different cancers. 
METTL3 adds a methyl molecule onto specific adenosine residues in the RNA, giving rise to the 
modification, N-6 methyl adenosine (m6A). Both METTL3 and m6A, depending on the cancer context 
have been shown to play tumorigenic and tumor-suppressive roles. In the case of PDAC, the role of 
METTL3/m6A methylation and the mechanisms of how it affects pancreatic cancer are not known. 
We sought to answer the above question to address this gap of knowledge.  
Based on our findings from investigating the relationship between METTL3 expression and overall 
pancreatic patient survival from TCGA, we hypothesized that METTL3 expression impacts pancreatic 
cancer progression. The specific aims designed to test this hypothesis were as follows: 
Aim 1: To investigate the effect of METTL3 on proliferative and migratory characteristics of 
pancreatic cancer cells 
Aim 2: To assess the effect of METTL3 loss on EMT-associated markers in pancreatic cancer cells 
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3. Materials and Methods: 
3.1 Analyzing TCGA dataset: 
 
METTL3 FPKM values of 156 patients in the TCGA PAAD cohort were analyzed against the 
clinical information from UC Xena. Based on average METTL3 expression, the patient cohort was 
divided into two groups: high METTL3 expressing and low METTL3 expressing. Kaplan Meier curves 
were plotted to determine the correlation between METTL3 expression and patient survival, with 
available clinical data. Patients with neuroendocrine carcinoma, mucinous adenocarcinoma, or any 
other categorization of the disease were removed from consideration in the cohort, as we strictly 
looked at PDAC patients. The METTL3 expression levels were also correlated with other relevant 
clinical information using statistical tools. 
3.2 Cell lines/cell culture: 
 
Human pancreatic cancer cell lines Panc-1, MiaPaca-2 and mouse PKCY cell lines were used in 
this study. The human lines were obtained from ATCC and cultured in Dulbecco’s modified eagle 
medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1x Penicillin-Strep (P/S) 
solution. Mouse PKCY cell lines were cultured from harvested pancreases of PKCY mice maintained as 
part of the lab’s animal protocol. These 2D mouse cell lines were also cultured in DMEM 
supplemented with 10% FBS and 1x P/S solution.  
3.3 Plasmid Production: 
 
Bacterial stocks of MISSION shRNA targeting human and mouse METTL3 were purchased from 
Sigma. The bacterial stock was streaked onto an agar plate using sterile techniques and allowed to 
incubate at 37 degree Celsius for 12-16 hours. Bacterial colonies that grew on the plate were picked 
and inoculated in LB broth of 5ml volume and allowed to shake in a temperature-controlled shaker 
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for 12-16 hours overnight at 37 degree Celsius. Plasmid was isolated from a portion of the starter 
culture using a mini-prep kit and sent for sanger sequencing to confirm the identity of the genetic 
sequence. The remaining starter culture was used to inoculate a bigger volume of LB broth to obtain 
more plasmid DNA using the maxi-prep kit as was appropriate according to the initial volume of the 
culture. Plasmid DNA that was obtained was stored at -20 degree Celsius and used for lentivirus 
production. 
3.4 Lentivirus Production: 
 
To produce lentivirus carrying the appropriate transfer plasmid (targeting human or mouse 
METTL3 in this context), we used HEK293T cells. A low passage number of HEK293T cells were plated 
and cultured in complete media containing DMEM, 10% FBS, 1x P/S, and 1mM sodium pyruvate for 
about 20-24 hours. The media was then changed to antibiotic-free media, followed by addition of the 
transfection mix to the plate. The transfection mix included the lentiviral packaging plasmid (psPAX2), 
the lentiviral envelope expressing plasmid (pMD2.G - VSV-G) and our desired transfer plasmid in a 
solution containing Opti-MEM and lipofectamine 3000. The cells were allowed to incubate with the 
transfection mix overnight, before changing the media back to complete media. The supernatant 
produced by the cells, which constituted the lentivirus produced was centrifuged, filtered, and flash 
frozen 48h later for further use. 
3.5 Transfection: 
 
The transfection protocol was adapted from Addgene to generate stable cell lines expressing 
our gene of interest (a knocked down version of the METTL3 gene in this case). Five different lentiviral 
dilutions were created in a 6-well plate with DMEM complete media containing 10ug/ml polybrene, 
along with a no-virus control. DMEM complete media constituted of DMEM with 10% FBS, 1x P/S, and 
4mM L-alanyl-L-glutamine. A reverse transduction was performed by seeding 50,000 cells into each 
16 
 
well of the 6-well plate, that already contained 0.5ml of the different lentiviral dilutions. The cells 
were incubated with the virus for 48-72h and monitored by observing under the microscope each day. 
Post the incubation, the media was changed to contain media containing puromycin to start the 
selection process. The no-virus control well was used to monitor the death of the cells and gauge the 
rate of selection in other wells. A particular well with the appropriate dilution of virus was selected 
based on the degree of cell killing using Poisson statistics principles to ensure that only one copy of 
the virus is incorporated into majority of the cells transfected. Once confluent, the growing polyclonal 
population of resistant cells in the selected well was expanded into a 10cm dish and further on in 
bigger plates. The polyclonal population obtained was tested for protein expression using Western 
Blotting and single-cell clones were created from them using a limiting dilution technique.  
Panc-1 and MiaPaca-2 cell lines were transfected with lentivirus containing shRNA sequence 
targeting the human METTL3 gene. Polyclonal and single-cell clones from them were obtained using 
the above-described protocol. This work was carried out by Dr. Fredrik Thege in the Andrew Rhim lab. 
Mouse PKCY lines were transfected with lentivirus containing shRNA sequence targeting the mouse 
METTL3 gene. Polyclonal populations from different mouse lines were created by the same protocol 
















(referred to as 




(referred to as 
shRNA 111)  
 
CCGGCCTCAGTGGATCTGTTGTGATCTCGAGATCACAACAGATCCACTGAGGTTTTTG  Mouse 
TRCN0000039112 
(referred to as 
shRNA 112)  
 
CCGGCGTCAGTATCTTGGGCAAATTCTCGAGAATTTGCCCAAGATACTGACGTTTTTG  Mouse 
TRCN0000039113 
(referred to as 
shRNA 113)  
 
CCGGGCACCCGCAAGATTGAGTTATCTCGAGATAACTCAATCTTGCGGGTGCTTTTTG  Mouse 
TRCN0000289812 CCGGCGTCAGTATCTTGGGCAAGTTCTCGAGAACTTGCCCAAGATACTGACGTTTTTG Human 










3.6 Western Blotting: 
 
Panc-1 and MiaPaca-2 METTL3 knockdown cell lines were plated in 6-well plates 48h prior to 
protein collection and allowed to grow to confluency. Protein lysates were collected from the cells by 
cell scraping upon addition of RIPA buffer. RIPA buffer was prepared by adding 1x volume of protease 
inhibitor. 60ul of RIPA buffer was used per well of a 6-well plate. Protein lysate obtained was shaken 
and mixed using a rotor at 4 degree Celsius for 45 minutes. The lysate was then centrifuged at 15000g 
for 10 minutes to remove debris. Protein supernatant obtained was quantified using Bio Rad DC 
Protein Quantification Assay.  
Total protein of 15ug was loaded into each well and a 4-15% BioRad gradient gel was used. 
We ran the gel at 60V for the first ten minutes and at 90V for the remainder of the time. Once the gel 
was separated enough (indicated by the Bio Rad Precision Plus Dual Color Standards Ladder), transfer 
to a PVDF membrane was carried out through the Bio Rad Trans-Blot Turbo Transfer system at a mixed 
setting of 25V, 7 min. Prior to transfer, the PVDF membrane was equilibrated in 1x Trans-Blot Turbo 
Transfer buffer and methanol for activation.  
Post transfer, the membrane was blocked for 2 hours at room temperature using 3% BSA in 
TBST. 1:2000 concentration of the primary anti-rabbit Abcam METTL3 antibody (EPR 18810; ab 
195352) was used, and the membrane was incubated overnight at 4 degree Celsius. The membrane 
was washed the next day thrice with TBST and incubated for 50 minutes at room temperature in 
1:2000 concentration of dilute HRP secondary antibodies. Post incubation, the membrane was 
washed thrice again in TBST and imaged using Bio Rad’s Clarity ECL chemiluminescent substrate. The 
gel images obtained on the Chemi Doc were processed using image analysis software, Fiji - Image J. 
Primary Antibodies used to determine EMT expression levels were Cell signalling systems anti-rabbit 
E-Cadherin at 1:1000 concentration, Cell Signalling systems anti-rabbit Vimentin at 1:1000 
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concentration, and BD Biosciences anti-mouse N-Cadherin at 1:1000 concentration. B-actin or Hsp90 
were used as internal loading controls, based on the size of the desired protein product. 
The same western blotting protocol was used on the PKCY mouse METTL3 knockdown cell lines as 
well. 
 
Antibody Clone Host species Concentration Manufacturer 
METTL3 EPR 18810; ab 
195352 
Rabbit 1:2000 Abcam 
E-Cadherin 24E10 mAb 
#3195 




Catalog no. - 
610920 
Mouse 1:1000 BD Biosciences 
Vimentin D21H3 mAb # 
5741 
Rabbit 1:1000 Cell Signaling 
systems 








3.7 Quantitative Polymerase Chain Reaction: 
 
Panc-1 and MiaPaca-2 METTL3 knockdown cells were plated in 6-well plates 48h prior to RNA 
extraction and allowed to grow to confluency. RNA lysates were collected from the cells by adding 
RLT buffer followed by cell scraping. The lysates were collected with the samples and buffers being 
kept on ice, to minimize RNA degradation. RLT buffer was prepared by adding 10ul B-mercaptoethanol 
for every 1000ul volume of buffer. The collected lysates were passed through a 25–27-gauge syringe 
about ten times to thoroughly homogenize the sample. The lysate was then passed through the 
Qiagen RNeasy mini kit column to isolate purified RNA. Isolated RNA was quantified using the 
Nanodrop 2000 to determine purity and concentration.  
2ug of isolated RNA was used to create cDNA using the Invitrogen Super Script Reverse 
Transcriptase III. 25-50ng/ul of generated cDNA was used in setting up the qPCR assay. Thermo 
Fisher’s Power SYBR Green Master Mix was used to make the working solution with cDNA along with 
appropriate primers. The reaction was set up in a 96-well plate and run according to manufacturer’s 
instructions. Relative gene expression was measured using the standard (delta (delta Ct)) comparison. 
Human beta-2-microglobulin was used as housekeeping internal control gene.  
3.8 Proliferation Assay: 
 
3000 cells/well were plated in 96-well plates in to assess the proliferative characteristics of 
Panc-1 and MiaPaca-2 METTL3 knockdown cell lines. 1x concentration of Incucyte NucRed was also 
added to the cells while plating as a nuclear stain to aid in the cell count. The plate was set up on an 
imaging schedule and the cells were allowed to grow in the Incucyte. Phase confluence and red object 
count images were taken every 4 hours for 5 days. After the completion of the 5 days, data collected 
was used to plot a growth curve of time vs cell count in knockdown and control conditions of these 
cell lines. Doubling times calculated from the growth curve statistics was used as a measure of 
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proliferative ability. Three independent experiments were conducted reproducibly, making it a 
sample size of n=3. 
3.9 Transwell Migration Assay: 
 
Transwell migration assay was performed to determine the migration rates of Panc-1 and 
MiaPaca-2 cell lines upon METTL3 knockdown. This assay measures the chemotactic ability of the cells 
migrating towards a chemo attractive gradient. Falcon Permeable Support for 6-well plate with 8.0um 
Transparent PET membrane sterile inserts from Corning were used in this study. 300000 cells/well 
were plated on top of the transwells in serum-free DMEM media (containing 1x P/S antibiotic) and 
allowed to migrate to the other side of the transwell. A chemo attractive gradient of serum was 
created by adding DMEM with 10% FBS (also containing 1x P/S antibiotic) on the other side of the 
transwell, making sure the media touches the membrane on the transwell on top of the well. Panc-1 
and MiaPaca-2 cells were tested and optimized to migrate for 24h and 16h, respectively prior to the 
experiment. Once the appropriate incubation times for each cell line were elapsed, media on top of 
the inserts were aspirated and the transwell was moved to a new plate. A cotton-tipped applicator 
was used to remove any remaining media and cells that may not have migrated from the top of the 
transwell. Fixing/staining solution was added to the underside of the transwell insert, now placed in 
a new plate, and allowed to incubate at room temperature for 15 minutes. Post incubation, the 
transwells were washed and allowed to dry, followed by imaging them on a microscope and counting 
the fraction of migrated cells. Composition of the fixing/staining solution is as follows: 
0.5g Crystal Violet (0.05% w/v) 
27ml 37% Formaldehyde (1%) 
100ml 10x PBS (1x) 
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10ml Methanol (1%) 
863ml Distilled water to make up volume to 1L 
3.10 Statistical Analysis: 
 
GraphPad Prism version 8 was used to statistically analyze the results obtained. Error bars 
represent standard error of the means. P-value ≤ 0.05 were considered statistically significant. N=3 
















4.1 METTL3 expression is positively correlated with survival in PDAC patients: 
 
To determine the correlation between overall survival and METTL3 expression levels in PDAC 
patients, METTL3 FPKM values from the TCGA-PAAD cohort and clinical information from USC Xena 
were used. The patient cohort, based on the average level of METTL3 expression was split into two 
groups – high METTL3 expressing, low METTL3 expressing. Based on the clinical survival data 
available, a Mantel-Cox (log rank) test was performed to analyze overall survival as a function of 
METTL3 gene expression levels. A Kaplan-Meier curve was plotted to visualize the correlation 
between survival and METTL3 expression levels. We found that the patient cohort expressing higher 
levels of METTL3 than average, tended to survive longer than the patient cohort lower than average 
levels of METTL3. The difference in median survival was 6 months significantly longer in the patient 
group that showed higher than average levels of METTL3. P-value for the log rank test was 0.04, 
which rejects the null hypothesis that both survival curves are not significantly different. We thus 
found that METTL3 expression positively correlated with survival. Median survival in days for each 































Figure 5: Analyzing TCGA PAAD Cohort Data - Kaplan-Meier curve depicting the correlation 
between overall survival rates and METTL3 expression in PDAC patients. Patients expressing high 
and low levels of METTL3 are shown in red and green, respectively. 
 
 
Patient group Median 
Survival 
(days) 
High METTL3 expressing 691 
Low METTL3 expressing 511 
Table 3: Median survival of high METTL3 expressing group is higher than the low METTL3 





4.2 Generating METTL3 knockdown cell lines: 
 
To investigate the effect of METTL3 on the proliferative and migratory properties of human 
pancreatic cancer cells, we set out to generate a cellular system devoid of METTL3 expression. Panc-
1, MiaPaca-2 and PKCY mouse cell lines were lentivirally transfected with the appropriate shRNA 
targeting human or mouse METTL3 gene using the adapted Addgene transfection protocol as 
described in the materials section. Dr. Fredrik Thege created single-cell clones from the transfected 
polyclonal populations of Panc-1 and MiaPaca-2 cell lines. The single-cell clones generated were 
assigned numbers and would from hereon be described as follows: 
Clone generated Nomenclature 
assigned 
Panc-1 METTL3 KD Clone 2 PC2 
Panc-1 METTL3 KD Clone 4 PC4 
Panc-1 METTL3 KD Clone 5 PC5 
Panc-1 METTL3 KD Clone 6 PC6 
Panc-1 Non-targeted control PNT 
MiaPaca-2 METTL3 KD Clone 5 MC5 
MiaPaca-2 METTL3 KD Clone 6 MC6 
MiaPaca-2 METTL3 KD Clone 7 MC7 
MiaPaca-2 METTL3 KD Clone 11 MC11 
MiaPaca-2 Non-targeted control MNT 
Table 4: Nomenclature assigned to the different knockdown clones generated 
Pancreases of mice with genotype p53 L/L Kras G12D p48Cre Rosa Y/Y (PKCY) were harvested 
and cultured to generate mouse METTL3 knockdown pancreatic cancer cell lines. In these mice, cre 
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expression (C) is driven under the pancreas-specific p48 promoter that allows for the expression of 
mutant G12D Kras (K), loss of the P53 allele (P), and expression of the lineage label marker YFP (Y). 
Mice containing these four alleles are hence termed PKCY mice. Mice with identifiers as described in 
Table 5 were utilized. Single-cell clones were not generated from these murine METTL3 knockdown 
polyclonal populations. 
Mouse number Genotype 
14292 p53 L/L Kras G12D p48Cre Rosa Y/Y (PKCY) 
16686 p53 L/L Kras G12D p48Cre Rosa Y/Y (PKCY) 
17315 p53 L/L Kras G12D p48Cre Rosa Y/Y (PKCY) 
Table 5: Identifier and genotype of the mice used to generate PKCY METTL3 knockdown cells 
 
Figure 5 and 6 as follows showcase the morphology of the MiaPaca-2 and Panc-1 METTL3 KD single 
cell clones respectively. MiaPaca-2 cells are mesenchymal-like cells with an elongated morphology. 
Panc-1 cells on the other hand are epithelial-like cells that are polygonal, adherent and exhibit a 
cobblestone like morphology. Panc-1 cells upon METTL3 KD do not exhibit a characteristic change in 
morphology, compared to the non-targeted control. Whereas MiaPaca-2 cells seem to become less 
elongated and more clustered, almost exhibiting an epithelial-like morphology compared to control, 























































4.3 Confirmation of METTL3 knockdown: 




























































A) Western blot denotes a decreased level of METTL3 expression in the Panc-1 single cell 
clones compared to the non-targeted control 
B) Bar graph indicates the level of METTL3 expression in the different Panc-1 single cell clones 
upon METTL3 knockdown  
 
To test the level of METTL3 expression in the cellular system generated, we performed western 
blotting. Single-cell clones generated from the Panc-1 METTL3 knockdown polyclonal population were 
tested for the knockdown in expression levels of METTL3 using Western Blotting. Western blots 
imaged were quantified to determine expression levels of METTL3 using Fiji Image J. The bar graphs 
indicate level of METTL3 expression the clones express post the knockdown. Average knockdown 
levels of METTL3 expression determined by obtaining protein from three different passages (n=3) are 
as follows. Average knockdown levels here indicate the level by which METTL3 expression was 
reduced in these clones, as shown: 
 
PC2 PC4 PC5 PC6 
AVG METTL3 KD% 75% 86% 92% 71% 
 
All Panc-1 METTL3 knockdown single cell clones show significantly reduced expression of 




























Figure 9: Confirmation of METTL3 knockdown in MiaPaca-2 cells using Western Blotting 
A) Western blot denotes a decreased level of METTL3 expression in the MiaPaca-2 single cell 
clones compared to the non-targeted control 
B) Bar graph indicates the level of METTL3 expression in the different MiaPaca-2 single cell 




































To test the level of METTL3 expression in the cellular system generated, we performed western 
blotting. Single-cell clones generated from the Panc-1 METTL3 knockdown polyclonal population 
were tested for the knockdown in expression levels of METTL3 using Western Blotting. Western 
blots imaged were quantified to determine expression levels of METTL3 using Fiji Image J. The bar 
graphs indicate level of METTL3 expression the clones express post the knockdown. Average 
knockdown levels of METTL3 expression determined by obtaining protein from three different 
passages (n=3) are as follows. Average knockdown levels here indicate the level by which METTL3 
expression was reduced in these clones, as shown: 
 
MC5 MC6 MC7 MC11 
AVG METTL3 KD% 73% 74% 81% 85% 
 
All MiaPaca-2 METTL3 knockdown single cell clones show significantly reduced expression of 






















Figure 10: Confirmation of METTL3 knockdown in Panc-1 cells using qPCR 
Bar graph indicates the level of METTL3 expressed by the Panc-1 single cell clones post shRNA 
knockdown of METTL3 
Single-cell clones generated from the Panc-1 METTL3 knockdown polyclonal population were 
tested for the knockdown in expression levels of METTL3 using quantitative polymerase chain reaction 
(qPCR). Average knockdown levels determined by obtaining protein from three different passages 
(n=3) are as follows: 
 
PC2 PC4 PC5 PC6 











































Figure 11: Confirmation of METTL3 knockdown in MiaPaca-2 cells using qPCR  
Bar graph indicates the level of METTL3 expressed by the MiaPaca-2 single cell clones post shRNA 
knockdown of METTL3 
Single-cell clones generated from the MiaPaca-2 METTL3 knockdown polyclonal population 
were tested for the knockdown in expression levels of METTL3 using quantitative polymerase chain 
reaction (qPCR). Average knockdown levels determined by obtaining protein from three different 
passages (n=3) are as follows: 
 
MC5 MC6 MC7 MC11 


































4.4 Proliferation assay 
4.4.1 METTL3 knockdown reduces proliferation rates in some Panc-1 clones 
 
Figure 12: Proliferation assay in Panc-1 cells - This figure shows the growth of Panc-1 METTL3 
knockdown clones imaged on a time course. The cells appear red upon incorporation of the Incucyte 
NucRed dye to aid in cellular counts. 






















Panc-1 METTL3 knockdown clones were plated in 96-well plates in duplicates in three 
independent experiments and allowed to grow in the Incucyte, while being imaged every 4 hours for 
5 days. Incucyte NucRed fluorescent dye was added to aid in cellular count. Using the NucRed dye as 
a marker to label nuclei, cellular counts over 5 days were used to plot growth curves. Population 
doubling times were extracted from the growth curves, using the exponential growth curve equation. 





While population doubling time of clones 5 and 6 (PC5, PC6) were significantly slower 
than the non-targeted control, doubling times of clones 2 and 4 were not significantly 
different from the non-targeted control. We observed that METTL3 knockdown, hence 
reduces proliferation rates in some METTL3 knockdown clones but not the others in Panc-1 
cells. 
 
PC2 PC4 PC5 PC6 PNT 
Population 
Doubling Time (h) 


















Figure 13: METTL3 knockdown reduces proliferation rates in some Panc-1 single cell clones 
A) Growth curve denotes the rate of proliferation in Panc-1 clones upon METTL3 knockdown 
compared to non-targeted control 
B) Doubling times of Panc-1 METTL3 knockdown clones extracted from the growth curve are 
depicted in this graph 
 


































4.4.2 METTL3 knockdown reduces proliferation rates in MiaPaca-2 cells 
Figure 14: Proliferation assay in MiaPaca-2 cells - This figure shows the growth of METTL3 
knockdown clones imaged on a time course. The cells appear red upon incorporation of the Incucyte 
NucRed dye to aid in cellular counts. 
 























MiaPaca-2 METTL3 knockdown clones were plated in 96-well plates in duplicates in three 
independent experiments and allowed to grow in the Incucyte, while being imaged every 4 hours for 
5 days. Incucyte NucRed fluorescent dye was added to aid in cellular count. Using the NucRed dye as 
a marker to label nuclei, cellular counts over 5 days were used to plot growth curves. Population 
doubling times were extracted from the growth curves, using the exponential growth curve equation. 
The population doubling times as compared against the non-targeted control are as follows: 
 
MC5 MC6 MC7 MC11 MNT 
Population 
Doubling Time (h) 
26.0 27.5 32.5 32.4 21.6 
 
All MiaPaca-2 METTL3 knockdown clones except clone 6 (MC6) showed a significantly slower 
proliferation rate compared to the non-targeted control. The population doubling time of the 
knockdown clones being higher than the non-targeted denotes that it takes longer for the clones to 
double their population, due to their slower growth rate. We observed that METTL3 knockdown, 
























Figure 15: METTL3 knockdown reduces proliferation rates in MiaPaca-2 single cell clones 
A) Growth curve denotes the rate of proliferation in MiaPaca-2 clones upon METTL3 
knockdown compared to non-targeted control 
B) Doubling times of MiaPaca-2 METTL3 knockdown clones extracted from the growth curve 





4.5 Migration assay 









Figure 16: METTL3 knockdown does not affect migration rates of Panc-1 clones 
A) Panc-1 clones that migrated to the bottom of the transwell are shown here post fixing and 
staining with crystal violet 
B) Bar graph indicates the number of cells that migrated in each of the METTL3 knockdown 
























To determine how METTL3 loss affects migration rates of pancreatic cancer cells,we conducted a 
transwell migration assay on Panc-1 METTL3 knockdown clones. 10% fetal bovine serum was used as 
chemotactic gradient. Panc-1 cells were allowed to migrate through the transwell for 24 hours, post 
which they were fixed and stained using crystal violet dye. The fixed and stained cells were observed 
under the microscope and images were captured. Automated cell counter as part of Fiji – Image J was 
used to count the number of cells that migrated to the bottom of the transwell. We observed no 
significant difference in the migration rates of the knockdown clones when compared to the non-
targeted control in Panc-1 cells. Though we observed no significant difference in the migration rates 















































A) MiaPaca-2 clones that migrated to the bottom of the transwell are shown here post fixing 
and staining with crystal violet 
B) Bar graph indicates the number of cells that migrated in each of the METTL3 knockdown 
clones compared to non-targeted control  
 
To determine how METTL3 loss affects migration rates of pancreatic cancer cells,we conducted a 
transwell migration assay on MiaPaca-2 METTL3 knockdown clones. 10% fetal bovine serum was used 
as chemotactic gradient. MiaPaca-2 cells were allowed to migrate through the transwell for 17 hours, 
post which they were fixed and stained using crystal violet dye. The fixed and stained cells were 
observed under the microscope and images were captured. Automated cell counter as part of Fiji – 
Image J was used to count the number of cells that migrated to the bottom of the transwell. We 
counted the total number of cells present at the bottom of the transwell and used that as a measure 
of the migration rate, since the knockdown clones as well as the non-targeted control were allowed 
to migrate for the same duration of time. We observed that the migration rates of three of the METTL3 
knockdown clones were significantly slower when compared to the non-targeted control in MiaPaca-
2 cells. Further investigation is needed to determine the variability in clone 6 and why the migration 












Figure 18: Confirming different shRNA plasmid sequences targeting murine METTL3 – Sanger 




































To investigate the effects METTL3 loss may have on murine pancreatic cancer cells, we sought 
to generate a METTL3 knockdown in PKCY cell lines. We purchased four different shRNA plasmid 
constructs that target the murine METTL3 gene and tested them to identify the plasmid sequence 
that yields in the most genetic knockdown of METTL3 expression. The plasmids were isolated from 
bacterial stocks purchased, through a miniprep protocol. The purified plasmid sequences were 






























Figure 19: Testing knockdown efficacy of different shRNA lentivirus targeting murine METTL3 
A) Western blot showing METTL3 expression levels in PKCY cells when transfected with each 
virus 
B) Bar graph denotes the level of METTL3 expression in PKCY cells when transfected with each 
virus tested. This allows us to identify the lentiviral construct that produces the most 
knockdown in METTL3 expression 
Four different shRNA plasmids (shRNA110, shRNA111, shRNA 112, shRNA 113) that target murine 
METTL3 were tested to determine their knockdown efficacies. We generated lentivirus from each of 
the plasmids and transfected one PKCY cell line, 14292 with each of the viruses. Protein from the 













transfected PKCY cells were then collected, and a western blot was run to determine the level of 
METTL3 knockdown in the bulk population. We noted that when the 14292 PKCY cells were 
transfected with shRNA 112, the level of METTL3 expression was lowest, as shown below: 





110 70% 30% 
111 37% 63% 
112 12% 88% 
113 29% 71% 
 
This implies that the shRNA 112 plasmid produces the most METTL3 knockdown. To add more 
biological replicates, we used the shRNA 112 virus and transfected two more PKCY cell lines, namely 
– 16686 and 17315 (genotypes described in Table 5). The METTL3 knockdown bulk cell population of 





14292 16686 17315 
Avg METTL3 KD% 88% 53% 84% 
 
Further experiments in the murine context were performed on these PKCY METTL3 





















14292 16686 17315 
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4.8 Determining levels of expression of EMT markers: 
4.8.1 METTL3 knockdown causes a decrease in E-Cadherin, increase in Vimentin, and does 






















Figure 20: E-cadherin expression is reduced in Panc-1 cells upon METTL3 knockdown 
A) Western blot denotes a decreased level of E-cadherin expression in the Panc-1 single cell 
clones compared to the non-targeted control 
B) Bar graph indicates the level of E-cadherin expression in the different Panc-1 single cell 
clones upon METTL3 knockdown  





































Figure 21: Vimentin expression is increased in Panc-1 cells upon METTL3 knockdown 
A) Western blot denotes an increased level of Vimentin expression in the Panc-1 single cell 
clones compared to the non-targeted control 
B) Bar graph indicates the level of Vimentin expression in the different Panc-1 single cell clones 
upon METTL3 knockdown  




































Figure 22: N-cadherin expression is not affected in Panc-1 cells upon METTL3 knockdown 
A) Western blot denotes an increased level of N-cadherin expression in some Panc-1 single cell 
clones compared to the non-targeted control 
B) Bar graph indicates the level of N-cadherin expression in the different Panc-1 single cell 
clones upon METTL3 knockdown  
C) N-Cadherin expression levels are quantified in Table C 
 
PC2 PC4 PC5 PC6 
Avg N-cad exp % 96% 3184% 2692% 611% 














In Panc-1 METTL3 knockdown single cell clones, there is a significant decrease in E-cadherin 
expression across all clones and a significant increase in Vimentin expression across all clones when 
compared to the non-targeted control.  
N-cadherin expression on the other hand, seems to not be influenced by METTL3 loss. One of 
the clones, PC6 shows a significant increase in N-cadherin expression upon METTL3 knockdown. Two 
of the other clones PC4 and PC5 also show a marked increase in N-cadherin expression, but due to 
high variability in the replicates, the expression is not significantly different from the NT control. Even 
though the difference is not statistically significant, the overall trend in Panc-1 clones is for an increase 







































MC5 MC6 MC7 MC11 
Avg METTL3 KD% 147% 128% 109% 145% 
 
Figure 23: Vimentin expression is seemingly increased in MiaPaca-2 cells upon METTL3 knockdown 
A) Western blot denotes a seemingly increased level of Vimentin expression in the MiaPaca-2 
single cell clones compared to the non-targeted control 
B) Bar graph indicates the level of Vimentin expression in the different MiaPaca-2 single cell 
clones upon METTL3 knockdown  
C) Vimentin expression levels are quantified in Table C 














Vimentin expression in MiaPaca-2 METTL3 knockdown single cell clones, seems to not be 
affected. All the clones show a marginal increase in Vimentin expression, but the expression is not 
significantly different from the NT control. We can conclude that Vimentin expression is not 


























4.8.3 Effect of METTL3 knockdown on E-Cadherin, Vimentin, and N-Cadherin expression in 



















14292 16686 17315 
Avg E-cad exp % 77% 95% 110% 
14292 NT 14292 KD 16686 NT 17315 NT 16686 KD 17315 KD 
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14292 16686 17315 
Avg Vimentin exp % 120% 697% 45% 
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Figure 24: Effect of METTL3 knockdown on EMT-associated proteins in PKCY cells is inconclusive 
A) Panel A shows the level of E-cadherin expression in METTL3 knockdown PKCY cells and their 
respective non-targeted controls  
B) Panel B shows the level of Vimentin expression in METTL3 knockdown PKCY cells and their 
respective non-targeted controls  
C) Panel C shows the level of N-cadherin expression in METTL3 knockdown PKCY cells and their 
respective non-targeted controls  
 
We observe that the level of expression of E-cadherin, Vimentin, and N-cadherin remain 
uninfluenced by METTL3 loss in PKCY cells. Increase or decrease in expression of EMT-associated 
proteins compared to non-targeted control is extensively variable across the different PKCY METTL3 
knockdown cell lines. This may be a function of the nature of the PKCY cell line. Be it an epithelial or 
mesenchymal-like cell line, having undergone malignant transformation, the way the cell line 
responds to METTL3 loss may be highly variable. Moreover, the increase or decrease in expression 
levels upon METTL3 knockdown are not significantly different from their respective non-targeted 
controls. We must bear in mind that these are METTL3 knockdown cell populations in bulk, not having 
had single cell clones cultured from each of them. This result could also be due to the heterogeneity 
in knockdown levels in a bulk population. These results cannot hence conclude that METTL3 loss has 
absolutely no effect on expression levels of E-cadherin, Vimentin, and N-cadherin. Further studies 












Pancreatic Ductal Adenocarcinoma is one of the most aggressive solid cancers, whose treatment 
is made more challenging by compounding factors like late diagnosis, rapid metastatic spread, and 
chemoresistance. Genetic perturbations are observed in well characterized sets of genes, known as 
genetic drivers of the disease. These signature mutational landscapes are commonly observed in high 
frequencies across the PDAC patient population. Despite the uniform mutational profiles, treatment 
outcomes vary drastically among patients.  
Recent studies have brought to attention, the need to therapeutically exploit epigenetic 
pathways, apart from only targeting genetic mutations to effectively combat PDAC. Dysregulation of 
epigenetic proteins and associated mechanisms have been implicated to contribute to the 
progression of the disease. DNA methylation, histone modifications, aberrant microRNA expression 
are some avenues of keen therapeutic interest due to the reversible nature of their effects.(43),(44)    
METTL3 being an important epigenetic regulator of RNA in the human body, we sought to 
understand the broader question of the role METTL3 plays in PDAC progression. We found that 
METTL3 expression positively correlates with survival in PDAC patients by analyzing data from the 
TCGA-PAAD cohort. Expression of METTL3 can potentially be used as a molecular prognostic factor in 
the diagnosis of PDAC.   This survival correlation, however, begs the question, is METTL3 playing the 
role of a tumor suppressor and being protective in PDAC? We hypothesized that since higher METTL3 
expression significantly extends survival by 6 months, presence of METTL3 does impact PDAC 
progression. From our in vitro loss of function studies, we find that METTL3 knockdown reduces 
proliferation and migration in MiaPaca-2 cells, but only reduces proliferation in Panc-1 cells. These 




METTL3 is crucial in early development and differentiation. It represses pluripotent identity and 
induces cell fate specification.(37),(45) In a malignant context, when a tumor undergoes epithelial to 
mesenchymal transition (EMT), the restoration of early embryonic transcriptional programs occurs. 
Hence, we wanted to understand the role of METTL3 in effecting EMT-associated proteins in PDAC. 
We found that in Panc-1 cells, there was a significant reduction in E-cadherin and a concordant 
increase in Vimentin upon METTL3 knockdown. The effect was inconclusive in MiaPaca-2 cells. But in 
Panc-1 cells, this is consistent with the EMT phenotype, where expression of an epithelial marker is 
reduced while expression of a mesenchymal marker is increased. If knocking down METTL3 induces 
an EMT-like phenotype, it can be argued that METTL3 plays a potentially protective role in PDAC. 
METTL3 has been previously shown to effect pathogenesis in cervical cancer by enriching abundance 
of m6A in Snail mRNA, thus inducing EMT in cancer.(41) Given our preliminary results, the mechanism 
of how METTL3 affects EMT induction in PDAC requires further investigation.  
We must consider that there may also be differences arising due to the nature of the cell lines. 
Panc-1 is an epithelial-like cell line whereas MiaPaca-2 is a mesenchymal-like cell line. Incorporating 
more biological replicates of the two types of cell lines can help answer the question of if the effect is 
dependent on the nature of the cell line. Another consideration to note is that this study used shRNA 
knockdown of METTL3 which is not a complete knockout of expression. Since m6A RNA methylation 
is highly crucial, the cells may have devised a strategy to compensate for the reduction in methylation 
without adverse outcomes. Utilizing METTL3 knockout CRISPR clones of pancreatic cancer cell lines 
can be an effective strategy to understand the behaviors of tumors completely devoid of METTL3. 
When it comes to the TCGA expression data, patient tissue samples like most pancreatic tumors are, 
may have been heterogenous with varied kinds of cell populations. We know that islet cells in the 
pancreas express high levels of METTL3. Hence, distinguishing the malignant compartment from 
normal pancreas, while performing RNA-Seq expression profiling is key to making an assertion.  
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Methylation is highly dynamic, reversible, and differs based on the tissue type, disease state, and 
other pathologies. Studies from other groups have indicated a dual role for METTL3/m6A methylation 
in tumors. METTL3 has been shown to be playing tumor promoting roles in lung cancer,(38) gastric 
cancer,(46) and acute myeloid leukemia.(47) Whereas in glioblastoma(48), renal cell carcinoma(40), 
and breast cancer(49) there is evidence to conclude that METTL3 plays the role of a tumor suppressor. 
A 2018 study found that knockdown of METTL3 increased the susceptibility of human pancreatic 
cancer cell lines to anti-cancer agents like cisplatin, gemcitabine, and 5-fluorouracil. They concluded 
that METTL3 promotes chemoresistance in pancreatic cancer cells.(50) Contradictory to their results, 
our study highlights an important clinical finding of patient overall survival positively correlating with 
METTL3 in PDAC. This can mean that the effect METTL3/m6A methylation exerts of PDAC must be 
examined at different temporal snapshots in the pathogenesis of the disease (initiation versus 
progression) to conclude a role with certainty.   
Interestingly, independent of the potential effect the m6A writer has on tumor behavior, reader, 
and eraser proteins of the m6A methylation cascade have also been implicated in cancers. FTO and 
ALKBH5 have both been implicated to be playing tumorigenic roles in glioblastoma.(48),(51) IGF2BP 
proteins have been shown to target MYC and promote cellular migration, invasion in liver cancers.(52) 
It has also been shown to not always be that the effect an m6A writer and an m6A eraser exert be 
counteractive. While METTL3 (writer) acts as an oncogene in AML,(39) FTO (eraser) also acts as an 
oncogene in AML.(53)  This dynamic interplay between the writers, readers, and erasers should be 
further explored for a better mechanistic insight in PDAC.  Regardless of the primary site of origin of 
the cancer, the volume of implication METTL3 possesses in pathophysiology of cancer, and the 
therapeutic potential of understanding its role in the disease are unmistakable.  
Methylated RNA Immunoprecipitation sequencing (MeRIP-Seq) is an antibody-dependent 
technique to help map m6A sites across the transcriptome.(30) Since METTL3 post-transcriptionally 
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affects RNA transcripts, MeRIP-Seq can be performed as future work to delineate the specific 
transcripts METTL3 targets. This can give us an insight into what effector pathways METTL3 employs 
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